Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce C Baguley

Showing results (1-10 of 138) with videos related to

Pageof 14
Sort By:
The Lancet. Oncology|March 8, 2003
Antivascular therapy of cancer: DMXAABruce C Baguley
Recent Patents on Anti-Cancer Drug Discovery|January 29, 2008
Tumor stem cell niches: a new functional framework for the action of anticancer drugsBruce C Baguley
Methods in Molecular Biology (Clifton, N.J.)|February 25, 2016
Classical and Targeted Anticancer Drugs: An Appraisal of Mechanisms of Multidrug ResistanceBruce C Baguley
Clinical Lung Cancer|May 10, 2011
Preclinical efficacy of vascular disrupting agents in non-small-cell lung cancerBruce C Baguley
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 3, 2002
Novel strategies for overcoming multidrug resistance in cancerBruce C Baguley
Molecular Biotechnology|August 19, 2010
Multiple drug resistance mechanisms in cancerBruce C Baguley
Frontiers in Bioscience (Landmark Edition)|January 4, 2011
The paradox of cancer cell apoptosisBruce C Baguley
Methods in Molecular Biology (Clifton, N.J.)|December 2, 2009
Multidrug resistance in cancerBruce C Baguley
Oncology Research|January 18, 2006
Do negative feedback oscillations drive variations in the length of the tumor cell division cycle?Bruce C Baguley, Elaine Marshall
Expert Review of Anticancer Therapy|October 18, 2002
Potential of DMXAA combination therapy for solid tumorsBruce C Baguley, William R Wilson
Pageof 14

Showing results (1-10 of 138) with videos related to

Sort By:
Pageof 14
The Lancet. Oncology|March 8, 2003
Antivascular therapy of cancer: DMXAABruce C Baguley
Recent Patents on Anti-Cancer Drug Discovery|January 29, 2008
Tumor stem cell niches: a new functional framework for the action of anticancer drugsBruce C Baguley
Methods in Molecular Biology (Clifton, N.J.)|February 25, 2016
Classical and Targeted Anticancer Drugs: An Appraisal of Mechanisms of Multidrug ResistanceBruce C Baguley
Clinical Lung Cancer|May 10, 2011
Preclinical efficacy of vascular disrupting agents in non-small-cell lung cancerBruce C Baguley
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 3, 2002
Novel strategies for overcoming multidrug resistance in cancerBruce C Baguley
Molecular Biotechnology|August 19, 2010
Multiple drug resistance mechanisms in cancerBruce C Baguley
Frontiers in Bioscience (Landmark Edition)|January 4, 2011
The paradox of cancer cell apoptosisBruce C Baguley
Methods in Molecular Biology (Clifton, N.J.)|December 2, 2009
Multidrug resistance in cancerBruce C Baguley
Oncology Research|January 18, 2006
Do negative feedback oscillations drive variations in the length of the tumor cell division cycle?Bruce C Baguley, Elaine Marshall
Expert Review of Anticancer Therapy|October 18, 2002
Potential of DMXAA combination therapy for solid tumorsBruce C Baguley, William R Wilson
Pageof 14